The New England Journal of Medicine Looks at the State of Telehealth

July 17, 2016
The New England Journal of Medicine has published a broad analytical overview of the state of telehealth, written by E. Ray Dorsey, M.D. and Eric J. Topol, M.D., and looking at some of the challenges and opportunities involved

The widely regarded New England Journal of Medicine on July 14 released online an article reviewing the “State of Telehealth,” authored by E. Ray Dorsey, M.D. and Eric J. Topol, M.D. The eight-page article focused on three broad trends that the authors see as shaping the trajectory of telehealth activity in the United States.

“The first” of the three trends, Drs. Dorsey and Topol state, “is the transformation of the application of telehealth from increasing access to healthcare to providing convenience and eventually reducing cost. The second is the expansion of telehealth from addressing acute conditions to also addressing episodic and chronic conditions. The third,” they say, “is the migration of telehealth from hospitals and satellite clinics to the home and mobile devices.”

As the authors note, “Just as the motivation for telehealth is expanding, so are its applications The earliest applications for telehealth were for acute conditions, such as trauma and stroke. In 1999, ‘telestroke,’ the provision of acute stroke care from a remote neurologist to a patient in an emergency department, was introduced to increase access to a highly effective time-sensitive fibrinolytic therapy (tissue plasminogen activator). In just 15 years,” they point out, telestroke became mainstream, and the largest care provider for patients with stroke in the country is now not a major medical center but a telemedicine company. More recently, telehealth has expanded, by means of diverse care models that include school visits by medical assistants, video calls, telephone calls, and online algorithms, to include care for episodic conditions, such as sinusitis.”

In looking at the third trend, the authors note that “Initial telehealth applications delivered care to patients in institutions such as hospitals and satellite clinics, which frequently required expensive technological systems and on-site clinical or technical support. With increasingly available broadband and portable diagnostic technologies,” they emphasize, “telehealth is rapidly moving to the home. For persons with chronic conditions, including the 2 million elderly persons who are essentially homebound, the patient-centered medical home will increasingly be the patient’s home.”

Among the key issues the authors look at are the limits and fragmentation of current insurance coverage for telehealth; issues around the quality of the patient-physician relationship, and fragmentation of care among multiple providers, and the potential for abuse (e.g., via the overprescribing of narcotics), legal issues, including state licensure laws and credentialing issues; and social issues, including the digital divide between middle-class patients with easy access to the Internet, and economically disadvantaged patients lacking that access.

Still, they conclude, “Despite financial disincentives and substantial barriers, telehealth continues to grow and is likely to spread over the next decade. The increasing number of reimbursement models will provide fertile ground for the growth of telehealth…” And, they say, “Evidence abounds for the proximity of a ‘tipping point’ in telehealth, in which adoption moves beyond early adopters, who are focused on the technology, to the majority, who are focused on pragmatic applications.”

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1